http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 05:31:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Guardant+Health+%28GH%29+call+put+ratio+1+call+to+6.9+puts+with+a+focus+on+September+150+and+160+puts/27000155.html <p>Guardant Health (NASDAQ: GH) 30-day option implied volatility is at 53; compared to its 52-week of 45 to 85. Call put ratio 1 call to 6.9 puts with a focus on September 150 and 160 puts.</p> http://www.streetinsider.com/Options/Guardant+Health+%28GH%29+call+put+ratio+1+call+to+6.9+puts+with+a+focus+on+September+150+and+160+puts/27000155.html Mon, 31 Aug 2026 05:31:17 -0400 GH http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+26++Filed+by%3A+Eltoukhy+Helmy/26991708.html si-local-file:///var/storage/secattach/20260827/26991708.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+26++Filed+by%3A+Eltoukhy+Helmy/26991708.html Thu, 27 Aug 2026 19:47:00 -0400 GH O.13848145 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+26++Filed+by%3A+Eltoukhy+Helmy/26991708.html si-local-file:///var/storage/secattach/20260827/26991708.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+26++Filed+by%3A+Eltoukhy+Helmy/26991708.html Thu, 27 Aug 2026 19:47:00 -0400 GH O.13848145 http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Guardant+Health+%28GH%29%2C+%24245M+Patent+Judgment+Risks+Seen+as+Managable+/26970876.html <p>TD Cowen analyst Dan Brennan reiterated a Buy rating and $210.00 price target on Guardant Health (NASDAQ: GH).</p><p>The analyst commented: "A federal court entered final judgment in TwinStrands patent case against GH resulting in ~$245M of damages & a 6% royalty on certain products thru 2033. GH traded -4.4% in a weak tape. While a negative GH sees multiple ways to challenge/mitigate the impact & in a 'worst-case' (challenges don't succeed) expects assay redesigns can cut future royalties to 0%. We view the risks as manageable"</p><p>For an analyst ratings summary and ratings history on Guardant Health <a href="http://www.streetinsider.com/rating_history.php?q=GH">click here</a>. For http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+Guardant+Health+%28GH%29%2C+%24245M+Patent+Judgment+Risks+Seen+as+Managable+/26970876.html Tue, 25 Aug 2026 07:34:41 -0400 GH http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+Talasaz+AmirAli/26969182.html si-local-file:///var/storage/secattach/20260824/26969182.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+Talasaz+AmirAli/26969182.html Mon, 24 Aug 2026 17:22:00 -0400 GH O.13848145 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+Talasaz+AmirAli/26969182.html si-local-file:///var/storage/secattach/20260824/26969182.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+Talasaz+AmirAli/26969182.html Mon, 24 Aug 2026 17:22:00 -0400 GH O.13848145 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+MIGNONE+ROBERTO/26969176.html si-local-file:///var/storage/secattach/20260824/26969176.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+MIGNONE+ROBERTO/26969176.html Mon, 24 Aug 2026 17:21:00 -0400 GH O.13848145 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+MIGNONE+ROBERTO/26969176.html si-local-file:///var/storage/secattach/20260824/26969176.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Guardant+Health%2C+Inc.+++++For%3A+Aug+21++Filed+by%3A+MIGNONE+ROBERTO/26969176.html Mon, 24 Aug 2026 17:21:00 -0400 GH O.13848145 http://www.streetinsider.com/Litigation/Guardant+Health+to+appeal+Delaware+patent+ruling+by+TwinStrand/26967183.html <p>Guardant Health (Nasdaq: GH) announced it will appeal a final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought by TwinStrand Biosciences, Inc. and the University of Washington. Execution of the judgment and collection of potential royalties will be stayed pending the appeal.</p><p>The court order, which defined the scope of royalties based on products that existed at the time of the 2023 trial, excludes current versions of Guardant's Reveal and Shield products, as many earlier versions have since been discontinued or upgraded. Guardant also stated it has validated design improvements to its http://www.streetinsider.com/Litigation/Guardant+Health+to+appeal+Delaware+patent+ruling+by+TwinStrand/26967183.html Mon, 24 Aug 2026 14:44:46 -0400 GH http://www.streetinsider.com/Corporate+News/Guardant+Health+to+appeal+Delaware+patent+ruling+by+TwinStrand/26967183.html <p>Guardant Health (Nasdaq: GH) announced it will appeal a final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought by TwinStrand Biosciences, Inc. and the University of Washington. Execution of the judgment and collection of potential royalties will be stayed pending the appeal.</p><p>The court order, which defined the scope of royalties based on products that existed at the time of the 2023 trial, excludes current versions of Guardant's Reveal and Shield products, as many earlier versions have since been discontinued or upgraded. Guardant also stated it has validated design improvements to its http://www.streetinsider.com/Corporate+News/Guardant+Health+to+appeal+Delaware+patent+ruling+by+TwinStrand/26967183.html Mon, 24 Aug 2026 14:44:46 -0400 GH http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Press+Releases/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html <ul class="bwlistdisc"> <li> <i>Current Guardant Reveal, Shield products excluded from final District Court order</i> </li> <li> <i>Company has validated Guardant360 design improvements to exclude impact of potential royalties</i> </li> </ul> <p> PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. </p><p> “We strongly disagree with this decision and will promptly be appealing for its overturn,” http://www.streetinsider.com/Business+Wire/Guardant+Health+to+Appeal+Federal+District+Court+Judgment/26967181.html Mon, 24 Aug 2026 14:44:00 -0400 A.01908724 A.50213484 GH O.13848145 O.20988509 O.29765439 http://www.streetinsider.com/Corporate+News/Court+awards+TwinStrand+%24245.2M+in+Guardant+Health+patent+case/26964119.html <p>A U.S. District Court in Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand Biosciences and the University of Washington in a patent infringement case against Guardant Health (Nasdaq: GH), awarding more than $245.2 million in damages, accrued royalties and interest.</p><p>The judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two patents — U.S. Patent Nos. 10,287,631 and 10,760,127 — underlying TwinStrand's Duplex Sequencing technology across 11 products and services.</p><p>The total award breaks down as follows: $83.4 million in damages for infringement through June 30, 2023; $19.5 million in supplemental damages for sales http://www.streetinsider.com/Corporate+News/Court+awards+TwinStrand+%24245.2M+in+Guardant+Health+patent+case/26964119.html Mon, 24 Aug 2026 07:03:40 -0400 GH http://www.streetinsider.com/Hot+Corp.+News/Court+awards+TwinStrand+%24245.2M+in+Guardant+Health+patent+case/26964119.html <p>A U.S. District Court in Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand Biosciences and the University of Washington in a patent infringement case against Guardant Health (Nasdaq: GH), awarding more than $245.2 million in damages, accrued royalties and interest.</p><p>The judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two patents — U.S. Patent Nos. 10,287,631 and 10,760,127 — underlying TwinStrand's Duplex Sequencing technology across 11 products and services.</p><p>The total award breaks down as follows: $83.4 million in damages for infringement through June 30, 2023; $19.5 million in supplemental damages for sales http://www.streetinsider.com/Hot+Corp.+News/Court+awards+TwinStrand+%24245.2M+in+Guardant+Health+patent+case/26964119.html Mon, 24 Aug 2026 07:03:40 -0400 GH http://www.streetinsider.com/Press+Releases/TwinStrand+Biosciences+Announces+Final+Judgment+in+Patent+Infringement+Suit+Against+Guardant+Health%2C+Awarding+TwinStrand+and+the+University+of+Washington+More+Than+%24245.2+Million+in+Damages%2C+Accrued+R/26964019.html <p class="bwalignc"> <i>Court preserves 2023 willful infringement verdict and orders a 6% royalty on sales of 11 Guardant Health products and services found to infringe two patents underlying TwinStrand Duplex Sequencing® technology</i> </p><p class="bwalignc"> <i>Court enters judgment in favor of TwinStrand and the University of Washington on validity of the asserted claims of both patents</i> </p> <p> SEATTLE--(BUSINESS WIRE)-- TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against http://www.streetinsider.com/Press+Releases/TwinStrand+Biosciences+Announces+Final+Judgment+in+Patent+Infringement+Suit+Against+Guardant+Health%2C+Awarding+TwinStrand+and+the+University+of+Washington+More+Than+%24245.2+Million+in+Damages%2C+Accrued+R/26964019.html Mon, 24 Aug 2026 07:00:00 -0400 A.01908724 A.10730398 A.32672504 A.50213484 GH O.13848145 O.16042605 O.16042608 O.20988509 O.29765439